The emerging diurnal regulation of EGFR activity by GR suggests that tumour progression driven by aberrant forms of RTKs is strongly suppressed during the active phase of the day, but it might reach full impact during the resting phase, when GC levels are low. Here, NR3C1 is linked to neoplasm.